Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BCMA CAR-T cell immunotherapy
- Development stage
- Unknown
- Lead developer
- Shanghai YaKe Biotechnology
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
BCMA CAR-T cell immunotherapy is an investigational chimeric antigen receptor T-cell (CAR-T) therapy targeting B-cell maturation antigen (BCMA, also known as TNFRSF17). BCMA is a cell surface receptor highly expressed on malignant plasma cells in multiple myeloma, making it an ideal therapeutic target. The therapy involves genetically engineering a patient's autologous T cells to express a CAR that specifically recognizes and binds to BCMA, leading to T-cell activation and the targeted destruction of myeloma cells. Qilu Hospital of Shandong University (Qingdao) is evaluating this cell therapy in a clinical study in China for the treatment of patients with relapsed or refractory multiple myeloma, utilizing lentiviral vectors supplied by Shanghai Yake Biotech.
- Other names
- anti-BCMA CAR-T cellsanti-BCMA CAR-T therapyBCMA CAR-T cell immunotherapyBCMA CAR-T cellsBCMA CAR-T-cell immunotherapyBCMA-CAR-T cells
02
Targets
BCMA (B-cell maturation antigen)
Beyond the preview
Go deeper on BCMA CAR-T cell immunotherapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BCMA CAR-T cell immunotherapy.